国产热热热精品,亚洲视频久久】日韩,三级婷婷在线久久,99人妻精品视频,精品九热人人肉肉在线,AV东京热一区二区,91po在线视频观看,久久激情宗合,青青草黄色手机视频

HK-Shenzhen pulls off a first under medical connect

By Chai Hua | HK EDITION | Updated: 2021-05-21 14:26
Share
Share - WeChat
Management teams from the University of Hong Kong-Shenzhen Hospital and China Resources Guangdong Pharmaceutical pose for a group photo with the first imported medicine and medical device under the connect on April 16. [Photo provided to China Daily]

Moreover, he said the new channel can expand sales of medical companies. The hospital is purchasing a further 10 titanium rods. Each patient needs only one or two rods.

Lo said safety concerns will ensure the quantity won't be extremely large initially. "The titanium rod producer has agreed to provide the equipment on the mainland because they knew Professor Cheung would perform the surgery," he added, stressing the result of each case is important for the drug and medical equipment producers.

According to HKU-SZH, four other innovative medications have been approved and will soon be put into pilot use at the hospital, following the first drug and device applications.

The first imported medicine under the connect program is Rho(D) immune globulin - a blood disease drug that was used clinically at the hospital on April 29. In addition, the clinical data collected from these applications could also help expedite national approval for related international drugs or devices.

The marketing of many medicines in Hong Kong is synchronized with the world because of mutual recognition, but the mainland needs to do its own clinical results for review and approval, said Huo Peiqiong, general manager of China Resources Guangdong Pharmaceutical - the import agent for the first drugs and equipment.

So registering in Hong Kong or launching the products in the Hong Kong market is much faster than on the mainland, she noted. For example, one drug can be listed in Hong Kong simultaneously in the United States or the United Kingdom.

The connect gives the green light for medicines that are already available in Hong Kong and Macao markets, so more international pharmaceutical enterprises would seek registration there because entering the two special administrative regions mean they could tap the Greater Bay Area or the entire mainland market sooner.

However, it wasn't plain sailing for reviewing, purchasing and transporting the first batch of drugs and device through the connect. Huo recalled it took more than two months to have them delivered.

Many innovative measures were needed to lay a solid foundation for the potential expansion of the connect to more mainland cities. But in the absence of national approval, the import agent had to communicate back and forth between local evaluation authorities and pharmaceutical enterprises to provide proper materials for review.

|<< Previous 1 2 3 4 Next   >>|
Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
沁源县| 古浪县| 红安县| 南川市| 璧山县| 宜丰县| 汤原县| 迁安市| 泾阳县| 邵阳市| 磴口县| 姚安县| 沂水县| 北京市| 揭东县| 大连市| 保靖县| 富平县| 沾益县| 涟水县| 榆中县| 铜陵市| 澄江县| 泰州市| 普安县| 铁力市| 甘孜县| 陵川县| 孝昌县| 通州区| 即墨市| 白河县| 绥化市| 沅陵县| 青海省| 溧水县| 大新县| 麟游县| 丹东市| 屏南县| 彭山县|